(P-104) Safety and tolerability of SYN-004 in allogeneic hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Virtual

Co-Author(s)

MS

Mark Schroeder, MD

Washington University School of Medicine
Saint Louis, Missouri, United States
HS

Hailey Sappington, MPH

Washington University School of Medicine
Saint Louis, Missouri, United States
GL

Gabbie Lampen, BS

Washington University School of Medicine
Saint Louis, Missouri, United States
KR

Kimberly Reske, MPH

Research coordinator
Washington University
St. Louis, Missouri, United States
TH

Tiffany Hink, BS; MT, ASCP

Research Lab Supervisor
Washington University
St. Louis, Missouri, United States
VJ

Victoria Joachimstaler, BS

Washington University School of Medicine
Saint Louis, Missouri, United States
JE

Jeremy Eisele, MBA

Washington University in St. Louis
Saint Louis, Missouri, United States
MK

Matthew R. Keller, MS

Database Adminstrator
Washington University in St. Louis
St. Louis, Missouri, United States
AB

Andrew Bristol, PhD

Theriva Biologics
Rockville, Maryland, United States
CL

Charles Le, PhD

Theriva Biologics
Rockville, Maryland, United States
SC

Sheila Connelly, PhD

Thervia Biologics
Rockville, Maryland, United States
MM

Michael Moenk, PhD

Charles River Laboratories
Skokie, Illinois, United States
VW

Vince Wacher, PhD

Theriva Biologics
Rockville, Maryland, United States
MK

Michael Kaleko, MD, PhD

Theriva Biologics
Rockville, Maryland, United States
Joseph L. Kuti, PharmD

Associate director
Hartford Hospital
Hartford, CT, United States
Margaret A A. Olsen, PhD, MPH

Professor
Washington University School of Medicine
St. Louis, Missouri, United States

Presenting Author(s)

Erik R. Dubberke, MD, MSPH

Professor
Washington University School of Medicine
Saint Louis, Missouri, United States